Evaluating circulating cell-free DNA and DNA integrity index as biomarkers in non-small cell lung cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Evaluating circulating cell-free DNA and DNA integrity index as biomarkers in non-small cell lung cancer ; volume:36 ; number:1 ; day:17 ; month:6 ; year:2024 ; pages:1-9 ; date:12.2024
Journal of the Egyptian National Cancer Institute / Egyptian National Cancer Institute; 36, Heft 1 (17.6.2024), 1-9, 12.2024
- Urheber
-
Ezzeldin, Nada
El-Lebedy, Dalia
Hassan, Mirhane
Shalaby, Alaa Omar
Hussein, Sabah Ahmed Mohamed
Gharib, Ahmed Mohamed
Hamdy, Gehan
Mohammed, Asmaa Mahmoud
Ramadan, Abeer
Sobeih, Mohamed Emam
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s43046-024-00219-1
- URN
-
urn:nbn:de:101:1-2407252119026.966168746083
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:59 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ezzeldin, Nada
- El-Lebedy, Dalia
- Hassan, Mirhane
- Shalaby, Alaa Omar
- Hussein, Sabah Ahmed Mohamed
- Gharib, Ahmed Mohamed
- Hamdy, Gehan
- Mohammed, Asmaa Mahmoud
- Ramadan, Abeer
- Sobeih, Mohamed Emam
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cell-free circulating tumor DNA in cancer
Quantifying circulating cell-free DNA in humans
Towards systematic nomenclature for cell-free DNA
Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients
The non-vesicle cell-free DNA (cfDNA) induces cell transformation associated with horizontal DNA transfer
Cell-free DNA promotes malignant transformation in non-tumor cells
Quantitative characterization of tumor cell-free DNA shortening
Circulating cell-free DNA use for diagnosing cholangiocarcinoma
Cancer treatment monitoring using cell-free DNA fragmentomes
Circulating tumor cells (CTCs) and circulating cell-free tumor DNA (ctDNA) as blood-based biomarkers for managing non-small cell lung cancer (NSCLC) patients
An in vitro CRISPR screen of cell-free DNA identifies apoptosis as the primary mediator of cell-free DNA release
Relationship of circulating cell-free DNA levels to cell-free fetal DNA levels, clinical characteristics and laboratory parameters in preeclampsia
Cell-free circulating tumor DNA in cancer
Quantifying circulating cell-free DNA in humans
Towards systematic nomenclature for cell-free DNA
Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients
The non-vesicle cell-free DNA (cfDNA) induces cell transformation associated with horizontal DNA transfer
Cell-free DNA promotes malignant transformation in non-tumor cells
Quantitative characterization of tumor cell-free DNA shortening
Circulating cell-free DNA use for diagnosing cholangiocarcinoma
Cancer treatment monitoring using cell-free DNA fragmentomes
Circulating tumor cells (CTCs) and circulating cell-free tumor DNA (ctDNA) as blood-based biomarkers for managing non-small cell lung cancer (NSCLC) patients
An in vitro CRISPR screen of cell-free DNA identifies apoptosis as the primary mediator of cell-free DNA release
Relationship of circulating cell-free DNA levels to cell-free fetal DNA levels, clinical characteristics and laboratory parameters in preeclampsia
Cell-free circulating tumor DNA in cancer
Quantifying circulating cell-free DNA in humans
Towards systematic nomenclature for cell-free DNA
Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients
The non-vesicle cell-free DNA (cfDNA) induces cell transformation associated with horizontal DNA transfer
Cell-free DNA promotes malignant transformation in non-tumor cells
Quantitative characterization of tumor cell-free DNA shortening
Circulating cell-free DNA use for diagnosing cholangiocarcinoma
Cancer treatment monitoring using cell-free DNA fragmentomes
Circulating tumor cells (CTCs) and circulating cell-free tumor DNA (ctDNA) as blood-based biomarkers for managing non-small cell lung cancer (NSCLC) patients
An in vitro CRISPR screen of cell-free DNA identifies apoptosis as the primary mediator of cell-free DNA release